Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iodomethane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8387 | 0.91 | — | — | |
| SCHEMBL9020695 | 0.91 | — | — | |
| SCHEMBL29025500 | 0.91 | ALDH1A1 (0.52) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| Methylamine SCHEMBL18497691 | 0.89 | KMT2A (0.47) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14856230 | 0.88 | KMT2A (0.56) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19172427 | 0.88 | KMT2A (0.56) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL227313 | 0.88 | KMT2A (0.56) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7757481 | 0.88 | KMT2A (0.56) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| Potassium SCHEMBL31451607 | 0.88 | — | — | |
| Iodide SCHEMBL28520795 | 0.88 | KMT2A (0.50) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA S L (ES) | 2015-10-22 | — | — | US | disclosed |
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2015-04-09 | — | — | US | disclosed |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L (ES) | 2015-01-01 | — | — | US | disclosed |
| EP-2721174-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | Traslational Cancer Drugs Pharma, S.L. (ES) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012175537-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2012-12-27 | — | — | WO | disclosed |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | KMT2A 929/4885MEN1 2480/4885CYP3A4 4154/4885 |
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | CHKA, CHKB, CEPT1 | KMT2A 356/4885MEN1 2001/4885CYP3A4 3749/4885 |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | KMT2A 929/4885MEN1 2480/4885CYP3A4 4154/4885 |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | CHKA, CHKB, DCK | KMT2A 1330/4885MEN1 3315/4885CYP3A4 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.